Total
0
Shares
Rhythm Biosciences (ASX:RHY) - Executive Chairman, Otto Buttula
Executive Chairman, Otto Buttula
Source: Rhythm Biosciences
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Rhythm Biosciences (RHY) restructures board and management team, effective immediately
  • Current Chair Otto Buttula has transitioned to the Executive Chair role and current CEO Glenn Gilbert has been appointed Managing Director
  • The company says these changes support its goal of commercialising its ColoSTAT product, which is a blood test aimed at detecting colorectal cancer
  • RHY shares have ended the day 5.18 per cent in the red to close at $1.74 each

Rhythm Biosciences (RHY) has restructured its board and management team, effective immediately.

The predictive diagnostics company claimed the shuffle would better reflect its current and near-term operating structure.

Current Chair Otto Buttula moved to the role of Executive Chair to formalise his executive involvement in supporting the company’s goal of commercialising the ColoSTAT product.

Additionally, CEO Glenn Gilbert has been appointed as Managing Director.

Mr Buttula commented on the board changes.

“The board has decided to make these changes at a pivotal time to leverage Glenn and my joint experience driving corporate and commercial scale up activities. Glenn has already established a robust platform that has positioned Rhythm to continue maximising value for all stakeholders,” he said.

Mr Buttula also said he considers the executive aspect for the role of Chair to be a short term, but important role, which will reportedly provide support to the company during a critical time.

Rhythm aims to transform the global mass market for colorectal cancer detection with its ColoSTAT low-cost blood test. Colorectal cancer is the third most common cancer in men and the second most common in women, accounting for an estimated 1.9 million new cases and 935,000 deaths per year.

Mr Buttula’s remuneration will change from $84,000 to $150,000 per annum, excluding superannuation, while Mr Gilbert’s remuneration will remain unchanged.

RHY shares ended the day 5.18 per cent in the red to close at $1.74 each.

RHY by the numbers
More From The Market Herald
Danodan Hempworks LLC - Founder, Daniel Stoops

" KijiKava Ltd (ASX:FIJ) acquires Danodan Hempworks and US patent

Medicinal kava company FijiKava (ASX:FIJ) completes the acquisition of Danodan Hempworks, including its CBD extraction US…
Pointerra (ASX:3DP) - Managing Director and Co Founder, Ian Olson

" Pointerra (ASX:3DP) ends December cash flow positive

In its December quarter, Pointerra (ASX:3DP) reports record cash receipts from customers.
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) buds cannabis oil distribution agreement in Germany

Little Green Pharma (ASX:LGP) enters a three-year distribution agreement to market its LGP cannabis oils in…

" St George Mining (ASX:SGQ) identifies further nickel targets at Mt Alexander

St George Mining (ASX:SGQ) identifies further nickel targets following a seismic survey at Mt Alexander in…